Holen Sie sich die Stockscreener-App
22.02
0.96%
0.21
Ideaya Biosciences Inc Aktie (IDYA) Neueste Nachrichten
IDEAYA Biosciences: Precision Oncology Pipeline and Synthetic Lethality Catalysts - AInvest
IDEAYA's First-in-Class Cancer Pipeline: Major Clinical Updates Coming at 10th Anniversary R&D Day - Stock Titan
IDEAYA Biosciences Inc. Stock Analysis and ForecastHigh-margin investment plays - jammulinksnews.com
Is IDEAYA Biosciences Inc. a good long term investmentRobust financial gains - jammulinksnews.com
What drives IDEAYA Biosciences Inc. stock priceOver 200% growth - Autocar Professional
Breakthrough Lung Cancer Drug IDE849 Shows First Human Results: 70+ Patient Data Coming at WCLC 2025 - Stock Titan
Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight - GlobeNewswire Inc.
What analysts say about IDEAYA Biosciences Inc. stockHigh-return market picks - jammulinksnews.com
IDEAYA Biosciences: TD Cowen initiates coverage with Buy rating. - AInvest
Promising Pipeline and Strategic Focus Drive Buy Rating for IDEAYA Biosciences - TipRanks
TD Cowen initiates Ideaya Biosciences stock with Buy rating By Investing.com - Investing.com Canada
autocarpro> 2025> What analysts say about IDEAYA Biosciences Inc. stockPhenomenal trading returns - Autocar Professional
IDEAYA Biosciences CEO Fireside Chat: Precision Medicine Updates at BTIG Conference - Stock Titan
(IDYA) Proactive Strategies - news.stocktradersdaily.com
Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionROI Driven Alerts - Newser
How IDEAYA Biosciences Inc. stock performs during market volatilityDaily Stock Radar - Newser
Ideaya Biosciences stock gets Neutral rating from Goldman Sachs By Investing.com - Investing.com Canada
Ideaya Biosciences price target lowered to $30 from $57 at RBC Capital - MSN
Ideaya Biosciences shares fall 2.68% intraday as Biocytogen Pharmaceuticals enters into a global licensing agreement with BeOne Medicines. - AInvest
RBC Capital Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $30 - 富途牛牛
Ideaya Biosciences stock price target lowered to $30 by RBC Capital - Investing.com Canada
RBC Cuts Price Target on IDEAYA Biosciences to $30 From $57, Keeps Outperform, Speculative Risk - MarketScreener
Here's Why We're Watching IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation - 富途牛牛
(IDYA) Long Term Investment Analysis - news.stocktradersdaily.com
IDEAYA Biosciences, Inc.(NasdaqGS:IDYA) dropped from Russell Small Cap Comp Growth Index - MarketScreener
IDEAYA Biosciences: A Precision Oncology Play Gains Momentum with Russell 2000 Inclusion - AInvest
Why IDEAYA's Russell Exit Could Be a Biotech Contrarian's Dream - AInvest
IDEAYA Biosciences: A CFO's Deal-Making Expertise Could Be the Catalyst for a Breakout Year - AInvest
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
This NRG Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Ideaya Biosciences shareholders elect directors and approve auditor at annual meeting - Investing.com
Rhumbline Advisers Increases Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Holdings Lifted by GAMMA Investing LLC - Defense World
Handelsbanken Fonder AB Raises Stock Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Cantor Fitzgerald Comments on IDYA FY2026 Earnings - Defense World
Transcript : IDEAYA Biosciences, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10 - MarketScreener
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):